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Background: We previously identified an individual (CAPSS), 
from the CAPRISA 002 cohort. with potent strain-specific neu-
tralization. This response mapped to the C3 region of gpl20 and 
was detected at 11 weeks post-infection ( wpi) and then later waned 
co-incident with virnl escape. A monoclonal antibody (CAP88-
CH06) was isolated at 34 wpi which utilized the IGHV4-39*01, 
D3-3*01 and J4*02 genes, had 5.9% divergence from gennline, 
and CDRH3 length of 17 amino acids. This study examined the 
evolution of the CAP88-CH06 heavy chain immunoglobulin 
genes over 121 weeks, starting from l 1 weeks of infectiotl. 
Methods: RNA and DNA were extracted from PBMCs from 
donor CAP88 at four time-points (11, 17, 38 and 121 wpi). The 
heavy chain VDJ region,~ ofIGHV4-39 gene were PCR amplified 
and sequenced by T!lumina MiSeq. The resulting sequences were 
blasted against a database of germline IGHV and IGHJ sequences 
from IMGT and compared to the CAP88-CH06 sequence. 
Results: We detected - 3,500 sequences that were highly re-
lated to CAP88-CH06. The majority (75%) of these w;re from 
RNA at 11 wpi (1,051 sequences, 39%), 17 wpi (l,625, 61%) 
and 1 sequence eat:h in 38 wpi and 121 wpi. This corresponded 
to the antibody response which first appeared at 11 wpi, peaked 
at 26 wpi and by 54 weeks had declined. Most of the DNA 
sequences were from 11 wpi (n = 761) followed by 38 wpi 
(n= 113) and fewer than JO from 17 \Vpi and 121 wpL The 38 
wpi DNA sequences were closely related to die 11 wpi se-
quences of both RNA and DNA. 
Conclusions: We have identifi.ed clonally related antibody se-
quences from 4 different time-point~ from CAP88 in both RNA 
mid DNA. The frequency of sequences in RNA corresponded 
with plasma neutralizing antibody titres. DNA-derived se-
q~ences from later Lime-points clustered in phylogenetic trees 
with RNA-derived sequences from earlier time-points, sug-
gesting _.that they were from the memory B cell compartment. 
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Background: HIV/AIDS remains one of the most serious cur-
rent threats to global public health. Although anti-HIV drugs 
have been effective among the wealthiest populations, a vaccine 
and/or new methods to prevent infections are needed lo control 
HlV globally. Strategies to combal HIV-I require strucrural 
knowledge of how antibodies recognize HIV envelope proteins 
and how the immune system eliminates viruses. Until recently, 
only a small number of broadly neutralizing antibodies against 
HlV-1 had been characterized, and the immunological ba~is for 
their breadth and potency remains poorly understood. However. 
it was recently demonstrated that antibodies could be engineered 
to greatly enhance their b readth and potency (Diskin et al., 
Science 2011). Unfortunately, this and other engineeting efforts 
have resulted in a decrease in antibody half-life in mouse and 
non-human primate models. This dccre~sc in half-life correlates 
with an increase in reactivity to a variety of antigens, termed 
polyreacti vity. 
Methods: In order to make better targets for passive delivery 
therapies, we are working to increase the half-life of antibodies 
while maintaining their breadth and potency using a variety of 
computational and strucmre-based techniques. One tedrnique in-
volves reducing the spatial aggregation propensity, in which an 
algorithm finds dynamically exposed hydrophobic patche~ on the 
surlace of proteins (Chennamsctty ct aL, PNAS 2009). To this end, 
we have constructed severd! mutations in regions that have been 
predicted to have high aggregation propensities, and have tested 
them for polyreactivity and potency in neutralizati.on assays. 
Results: Initial results show rhat these novel reagents have re-
duced polyreactivily, yet they still maintain their potency in 
in vitro neutn1lization assays. 
Conclusions: \Ve are currently pursuing in vivo experiments in 
mice to further understand the relationship between antibody 
potency, polyrcaetivity, and half-life. 
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Background: Broadly neutralizing antibodies (hNAh~) are be-
ing developed for topical and systemic pre-exposure prophy-
Jaxi.~. Since some bNAbs (e.g. 4£10) have been reported to 
internet with non-viral cpitopes, the cross-reactivity of bNAbs is 
an important safety parameter to be documented in regulatory 
submissions. The objective of this study was to determine the 
cross-reactivity of Nicotiana (-N) manufactured anti-HIV 
bNAbs 4El0-N and VRCOl-N, and anti-HSV glycoprotein D 
bNAb HSV8-N with cryoscctio ns of human tissues. 
Methods: In order to detect binding, the antibodies were hioti-
nylated and applied to cryoscctions of normal human tissues (3 
donors per tissue) at two concentrations (2-20 µg/ml). Com-
mercially available Synagis was biotinylated and used as a 
control. The stUdy wa~ GLP compliant. 
Results: 4El0-N variably stained a variety of tissue elements in 
the human tissue panel VRCOl-N also produced stainin<> of 
tissue elements; however, the staining with VRCO!-N ~·as 
generally present in fewer tissues and with reduced intensity a~d 
frequency. No staining with HSV8, N or Synagis was observed 
in the human tissue panel examined. 
~onclusions: The majority of ob&erved staining was cytoplasmic 
m nature, which is of little tox:icologic concem since the cyto-
plasmic compartment is generally considered to be inaccessible to 
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